Frank Struyf

13.7k total citations
60 papers, 1.7k citations indexed

About

Frank Struyf is a scholar working on Epidemiology, Surgery and Immunology. According to data from OpenAlex, Frank Struyf has authored 60 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Epidemiology, 27 papers in Surgery and 12 papers in Immunology. Recurrent topics in Frank Struyf's work include Cervical Cancer and HPV Research (36 papers), Hepatitis B Virus Studies (31 papers) and Genital Health and Disease (22 papers). Frank Struyf is often cited by papers focused on Cervical Cancer and HPV Research (36 papers), Hepatitis B Virus Studies (31 papers) and Genital Health and Disease (22 papers). Frank Struyf collaborates with scholars based in Belgium, United States and Netherlands. Frank Struyf's co-authors include Gary Dubin, Marie‐Pierre David, Rolando Herrero, Allan Hildesheim, Sholom Wacholder, Lan Lin, P.V. Suryakiran, S. Rachel Skinner, Patricia G. Spear and Wim Quint and has published in prestigious journals such as Gastroenterology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Frank Struyf

59 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank Struyf Belgium	23	1.4k	498	365	185	155	60	1.7k
Alain Luxembourg United States	27	1.2k 0.8×	366 0.7×	523 1.4×	208 1.1×	92 0.6×	76	1.8k
Judith F. Smith United States	16	1.0k 0.7×	330 0.7×	366 1.0×	193 1.0×	78 0.5×	18	1.4k
John Schussler United States	19	1.9k 1.3×	794 1.6×	202 0.6×	301 1.6×	289 1.9×	35	2.0k
D R Lowy United States	9	1.2k 0.9×	265 0.5×	551 1.5×	248 1.3×	109 0.7×	12	1.5k
Sam Hibbitts United Kingdom	20	654 0.5×	213 0.4×	394 1.1×	190 1.0×	82 0.5×	34	1.3k
Merilyn Hibma New Zealand	22	810 0.6×	174 0.3×	412 1.1×	376 2.0×	76 0.5×	56	1.4k
Keshu Shan China	7	2.4k 1.7×	948 1.9×	456 1.2×	609 3.3×	287 1.9×	13	2.9k
Linda Struijk Netherlands	22	1.5k 1.1×	550 1.1×	183 0.5×	229 1.2×	107 0.7×	39	1.9k
Maria Gabriella Donà Italy	20	667 0.5×	402 0.8×	85 0.2×	188 1.0×	59 0.4×	72	1.1k
Martine Wettendorff Belgium	16	785 0.6×	116 0.2×	666 1.8×	287 1.6×	49 0.3×	24	1.4k

Countries citing papers authored by Frank Struyf

Since Specialization

Citations

This map shows the geographic impact of Frank Struyf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Struyf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Struyf more than expected).

Fields of papers citing papers by Frank Struyf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Struyf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Struyf. The network helps show where Frank Struyf may publish in the future.

Co-authorship network of co-authors of Frank Struyf

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Struyf. A scholar is included among the top collaborators of Frank Struyf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Struyf. Frank Struyf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaissière, Nathalie, Carla Truyers, Erik Buntinx, et al.. (2025). Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial. EClinicalMedicine. 79. 103016–103016. 1 indexed citations

Robinson, Cynthia, Benoît Baron, D. Lowson, et al.. (2025). Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy. Human Vaccines & Immunotherapeutics. 21(1). 2538340–2538340. 1 indexed citations

Gars, Mathieu Le, Jerald Sadoff, Vicky Cárdenas, et al.. (2024). Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial. Vaccine. 42(19). 3938–3952.

Kristyanto, Hendy, Leen Slaets, Ilse Scheys, et al.. (2024). Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines. Journal of Thrombosis and Haemostasis. 22(12). 3532–3541. 1 indexed citations

Cárdenas, Vicky, Mathieu Le Gars, Carla Truyers, et al.. (2024). Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine. 42(16). 3536–3546. 2 indexed citations

Lehtinen, Matti, Dan Apter, Tiina Eriksson, et al.. (2021). Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland. Cancer Medicine. 10(21). 7759–7771. 3 indexed citations

Schwarz, Tino F., Li‐Min Huang, Alejandra Valencia, et al.. (2019). A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Human Vaccines & Immunotherapeutics. 15(7-8). 1970–1979. 45 indexed citations

Lin, Lan, et al.. (2018). Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4–6-year-old Girls. The Pediatric Infectious Disease Journal. 37(4). e93–e102. 9 indexed citations

Lehtinen, Matti, Camilla Lagheden, Tapio Luostarinen, et al.. (2017). Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. BMJ Open. 7(8). e015867–e015867. 72 indexed citations

10.

Leung, Ting Fan, Fong Seng Lim, Franck Thollot, et al.. (2017). Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial. Vaccine. 36(1). 98–106. 22 indexed citations

11.

Romanowski, Barbara, Tino F. Schwarz, Linda Ferguson, et al.. (2015). Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Human Vaccines & Immunotherapeutics. 12(1). 20–29. 70 indexed citations

12.

Kreimer, Aimée R., Frank Struyf, Maria Rowena Del Rosario‐Raymundo, et al.. (2015). Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. The Lancet Oncology. 16(7). 775–786. 214 indexed citations

13.

Leung, Ting Fan, Fong Seng Lim, Franck Thollot, et al.. (2015). Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Human Vaccines & Immunotherapeutics. 11(7). 1689–1702. 41 indexed citations

14.

Romanowski, Barbara, Tino F. Schwarz, Linda M. Ferguson, et al.. (2014). Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Human Vaccines & Immunotherapeutics. 10(5). 1155–1165. 85 indexed citations

15.

Taylor, Sylvia, Frank Struyf, Fernanda Tavares Da Silva, et al.. (2014). Strategies for continuous evaluation of the benefit–risk profile of HPV-16/18-AS04-adjuvanted vaccine. Expert Review of Vaccines. 13(11). 1297–1306. 8 indexed citations

16.

Quint, Wim, David Jenkins, Anco Molijn, et al.. (2011). One virus, one lesion—individual components of CIN lesions contain a specific HPV type. The Journal of Pathology. 227(1). 62–71. 156 indexed citations

17.

Rector, Annabel, Philippe Lemey, Els Keyaerts, et al.. (2001). Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s disease. Genes and Immunity. 2(6). 323–328. 43 indexed citations

18.

Rector, Annabel, Séverine Vermeire, Inge Thoelen, et al.. (2001). Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Human Genetics. 108(3). 190–193. 28 indexed citations

19.

Struyf, Frank, et al.. (1999). Usefulness of Immunochromatographic Detection of Antibodies to Mycobacterium tuberculosis as an Adjunct to Auramine Staining for Rapid Diagnosis of Tuberculosis in a Low-Prevalence Setting. European Journal of Clinical Microbiology & Infectious Diseases. 18(10). 740–742. 3 indexed citations

20.

Struyf, Frank, et al.. (1998). Evaluation of Glucocard Memory 2 and Accutrend^® Sensor Blood Glucose Meters. Clinical Chemistry and Laboratory Medicine (CCLM). 36(1). 47–52. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact